549-18-8
|
Amitriptyline hcl
|
Innovators:
Merck & Co.
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
CEPJapan DMFKorea DMFUS DMFOther
|
|
|
|
59277-89-3
|
Acyclovir
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)N - OPHTHALMIC
|
Available dmf:
Canada DMFCEPKorea DMFUS DMF
|
|
|
|
850140-73-7
|
Afatinib dimaleate
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
66734-13-2
|
Alclometasone dipropionate
|
Innovators:
Schering-Plough
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
Japan DMFUS DMF
|
|
|
|
260055-05-8
|
Alendronate sodium
|
Innovators:
Merck & Co.
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
Canada DMFEU DMFJapan DMFUS DMF
|
|
|
|
315-30-0
|
Allopurinol
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Canada DMFCEPJapan DMFUS DMFOther
|
|
|
|
51022-69-6
|
Amcinonide
|
Innovators:
Astellas
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
Canada DMFEU DMFJapan DMFUS DMF
|
|
|
|
154229-18-2
|
Abiraterone Acetate
|
Innovators:
McNeil
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMFUS DMF
|
|
|
|
90779-69-4
|
Atosiban Acetate
|
Innovators:
Ferring
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMF
|
|
|
|
64228-81-5
|
Atracurium besylate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
Canada DMFCEPEU DMFUS DMFOther
|
|
|
|
320-67-2
|
Azacitidine
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFUS DMF
|
|
|
|
83905-01-5
|
Azithromycin dihydrate
|
Innovators:
Pfizer
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)N - OPHTHALMIC
|
Available dmf:
Brazil DMFCanada DMFCEPUS DMFOther
|
|
|
|
78110-38-0
|
Aztreonam
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMF
|
|
|
|
120511-73-1
|
Anastrozole
|
Innovators:
Astra Zeneca
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Canada DMFCEPJapan DMFUS DMFOther
|
|
|
|
166663-25-8
|
Anidulafungin
|
Innovators:
Eli Lilly
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
-
|
|
|
|
503612-47-3
|
Apixaban
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
608141-41-9
|
Apremilast
|
Innovators:
Celgenex
|
Therapeutic category:
A - ORAL SOLID ORDINARY
|
Formulation:
M-MUSCULO-SKELETAL SYSTEM
|
Available dmf:
-
|
|
|
|
129722-12-9
|
Aripiprazole
|
Innovators:
Otsuka
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…) G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
EU DMFJapan DMFKorea DMFUS DMFOther
|
|
|
|
29122-68-7
|
Atenolol
|
Innovators:
Astra Zeneca
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPUS DMFJapan DMF
|
|
|
|
82248-59-7
|
Atomoxetine hcl
|
Innovators:
Eli Lilly
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
Canada DMFEU DMFKorea DMFUS DMF
|
|
|
|
134523-03-08
|
Atorvastatin calcium
|
Innovators:
Pfizer
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Brazil DMFCanada DMFCEPEU DMFKorea DMFUS DMFOther
|
|
|
|
90779-69-4
|
Atosiban Acetate
|
Innovators:
Ferring
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMF
|
|
|
|
64228-81-5
|
Atracurium besylate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
Canada DMFCEPEU DMFUS DMFOther
|
|
|
| |
5534-09-8
|
Beclomethasone dipropionate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)P - OTICQ - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
CEPJapan DMFUS DMFEU DMFOther
|
|
|
|
987-24-6
|
Betamethasone acetate
|
Innovators:
Schering-Plough
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMF
|
|
|
|
378-44-9
|
Betamethasone base
|
Innovators:
Schering-Plough
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)N - OPHTHALMIC
|
Available dmf:
Japan DMFCEP
|
|
|
|
5593-20-4
|
Betamethasone dipropionate
|
Innovators:
Schering-Plough
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
2152-44-5
|
Betamethasone valerate
|
Innovators:
Schering-Plough
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFCEPEU DMFCanada DMFOther
|
|
|
|
90357-06-5
|
Bicalutamide
|
Innovators:
Astra Zeneca
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMFCEPOther
|
|
|
|
155206-00-1
|
Bimatoprost
|
Innovators:
Allergan
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
US DMFEU DMFCanada DMF
|
|
|
|
9041-93-4
|
Bleomycin sulfate
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
390800-88-1
|
Bortezomib
|
Innovators:
Millennium Pharma
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMFBrazil DMFJapan DMFOther
|
|
|
|
913611-97-9
|
Brexpiprazole
|
Innovators:
Otsuka
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
22260-51-1
|
Bromocriptine mesylate
|
Innovators:
Novartis
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCEPCanada DMFBrazil DMFOther
|
|
|
|
51333-22-3
|
Budesonide
|
Innovators:
Astra Zeneca
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGH - RECTAL SYSTEMIC (Suppositories)Q - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFJapan DMFEU DMFCEPOther
|
|
|
|
52485-79-7
|
Buprenorphine base
|
Innovators:
Lohmann Therapy Systems
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCEP
|
|
|
|
53152-21-9
|
Buprenorphine hcl
|
Innovators:
Indivior Inc.
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCanada DMFCEP
|
|
|
|
58786-99-5
|
Butorphanol tartrate
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)I - NASAL SYSTEMIC
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
2152-44-5
|
Betamethasone valerate
|
Innovators:
Schering-Plough
|
Therapeutic category:
D-DERMATOLOGICALS )
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…
|
Available dmf:
US DMFJapan DMFCEPEU DMFCanada DMFOther
|
|
|
| | |
15663-27-1
|
Cisplatin
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
CEPEU DMF
|
|
|
|
81103-11-9
|
Clarithromycin
|
Innovators:
AbbVie Inc
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFCEPKorea DMF
|
|
|
|
25122-46-7
|
Clobetasol propionate
|
Innovators:
Lab. Galderma
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFCEPCanada DMFKorea DMFEU DMFOther
|
|
|
|
1402820-62-5
|
Cabazitaxel
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
81409-90-7
|
Cabergoline
|
Innovators:
Pfizer
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFEU DMFCEPKorea DMFBrazil DMFOther
|
|
|
|
112965-21-6
|
Calcipotriene (calcipotriol)
|
Innovators:
LEO Pharma
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFCEPEU DMFCanada DMFOther
|
|
|
|
32222-06-3
|
Calcitriol
|
Innovators:
Abbvie
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFCEPEU DMF
|
|
|
|
154361-50-9
|
Capecitabine
|
Innovators:
Roche
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPUS DMFEU DMFCanada DMFOther
|
|
|
|
38821-49-7
|
Carbidopa
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFJapan DMFCEPEU DMFCanada DMFOther
|
|
|
|
41575-94-4
|
Carboplatin
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPEU DMF
|
|
|
|
868540-17-4
|
Carfilzomib
|
Innovators:
Amgen
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
-
|
|
|
|
72956-09-3
|
Carvedilol base
|
Innovators:
Roche
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCEPKorea DMFOther
|
|
|
|
610309-89-2
|
Carvedilol phosphate
|
Innovators:
Roche
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFOther
|
|
|
|
162808-62-0
|
Caspofungin acetate
|
Innovators:
Merck & Co.
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFBrazil DMFOther
|
|
|
|
302-22-7
|
Chlormadinone acetate
|
Innovators:
Pfizer
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Japan DMFEU DMF
|
|
|
|
59865-13-3
|
Ciclosporin
|
Innovators:
Novartis
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)N - OPHTHALMIC
|
Available dmf:
Japan DMFUS DMFCanada DMFCEPKorea DMFEU DMFOther
|
|
|
|
73963-72-1
|
Cilostazol
|
Innovators:
Otsuka
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFJapan DMFKorea DMFEU DMFOther
|
|
|
|
364782-34-3
|
Cinacalcet hcl
|
Innovators:
Amgen
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMF
|
|
|
|
96946-42-8
|
Cisatracurium besylate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMF
|
|
|
|
120202-66-6
|
Clopidogrel bisulfate
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPCanada DMFEU DMFUS DMFKorea DMFOther
|
|
|
|
1004316-88-4
|
Cobicistat
|
Innovators:
Gilead Sciences
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
427-51-0
|
Cyproterone acetate
|
Innovators:
Bayer
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCEP
|
|
|
| | |
872728-81-9
|
Dabigatran etexilate
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMF
|
|
|
|
133099-07-7
|
Darifenacin hbr
|
Innovators:
Novartis
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
B - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMF
|
|
|
|
302962-49-8
|
Dasatinib anhydrous
|
Innovators:
Bristol-Myers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMF
|
|
|
|
863127-77-9
|
Dasatinib monohydrate
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
23541-50-6
|
Daunorubicin hcl
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
201530-41-8
|
Deferasirox
|
Innovators:
Novartis
|
Therapeutic category:
V-VARIOUS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFBrazil DMFOther
|
|
|
|
138-14-7
|
Deferoxamine mesylate
|
Innovators:
Novartis
|
Therapeutic category:
V-VARIOUS
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
CEPUS DMFEU DMFBrazil DMFOther
|
|
|
|
20423-99-8
|
Deprodone propionate
|
Innovators:
Abbott
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
Japan DMF
|
|
|
|
100643-71-8
|
Desloratadine
|
Innovators:
Schering-Plough
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
62357-86-2
|
Desmopressin acetate
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)I - NASAL SYSTEMIC
|
Available dmf:
US DMFCEPEU DMFOther
|
|
|
|
638-94-8
|
Desonide
|
Innovators:
Lab. Galderma
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
808-48-0
|
Desoxycorticosterone (Desoxycortone) Pivalate
|
Innovators:
Schering-Plough
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
EU DMF
|
|
|
|
93413-62-8
|
Desvenlafaxine base
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
B - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
93414-01-1
|
Desvenlafaxine fumarate
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
B - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMF
|
|
|
|
386750-22-7
|
Desvenlafaxine succinate
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
B - ORAL SOLID LONG-ACTING 2
|
Available dmf:
US DMFCanada DMFOther
|
|
|
|
33755-46-3
|
Dexamethasone -17 valerate
|
Innovators:
D-DERMATOLOGICALS
|
Therapeutic category:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Formulation:
Japan DMF
|
Available dmf:
-
|
|
|
|
364-98-7
|
Diazoxide
|
Innovators:
Schering-Plough
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFJapan DMF
|
|
|
|
33564-31-7
|
Diflorasone diacetate
|
Innovators:
Pfizer
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMF
|
|
|
|
23674-86-4
|
Difluprednate
|
Innovators:
Mitsubishi Chemical
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)N - OPHTHALMIC
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMFOther
|
|
|
|
6190-39-2
|
Dihydroergotamine mesylate
|
Innovators:
Novartis
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)I - NASAL SYSTEMIC
|
Available dmf:
US DMFCEPOther
|
|
|
|
8067-24-1
|
Dihydroergotoxine mesylate
|
Innovators:
Novartis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCEPOther
|
|
|
|
33286-22-5
|
Diltiazem hcl
|
Innovators:
Mitsubishi Tanabe Pharma
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
Canada DMFUS DMFCEP
|
|
|
|
624-49-7
|
Dimethyl fumarate
|
Innovators:
Biogen Idec
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
EU DMFUS DMF
|
|
|
|
165800-07-7
|
Disodium Zoledronate
|
Innovators:
Axsome Therapeutics
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
-
|
Available dmf:
-
|
|
|
|
114977-28-5
|
Docetaxel
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFUS DMFCanada DMFKorea DMFJapan DMFOther
|
|
|
|
120014-06-1
|
Donepezil hcl
|
Innovators:
Eisai
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
Canada DMFEU DMFUS DMFJapan DMFOther
|
|
|
|
130693-82-2
|
Dorzolamide hcl
|
Innovators:
Merck & Co.
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
US DMFCanada DMFCEP
|
|
|
|
1229-29-4
|
Doxepin hcl
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCEPEU DMF
|
|
|
|
54573-75-0
|
Doxercalciferol
|
Innovators:
Genzyme
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMF
|
|
|
|
25316-40-9
|
Doxorubicin hcl
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFJapan DMFCEPCanada DMFOther
|
|
|
|
67392-87-4
|
Drospirenone
|
Innovators:
Bayer
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFCanada DMFCEPKorea DMFOther
|
|
|
|
136434-34-9
|
Duloxetine hcl
|
Innovators:
Eli Lilly
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPEU DMFUS DMFCanada DMFKorea DMF
|
|
|
| |
480449-70-5
|
Edoxaban
|
Innovators:
Daiichi
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
104121-92-8
|
Eldecalcitol
|
Innovators:
Chugai Pharma
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
177834-92-3
|
Eletriptan hbr
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
496775-61-2
|
Eltrombopag olamine
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
864821-90-9
|
Eluxadoline
|
Innovators:
Allergan
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
864070-44-0
|
Empagliflozin
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
56390-09-1
|
Epirubicin hcl
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
Canada DMFCEPEU DMFJapan DMFUS DMFKorea DMFOther
|
|
|
|
188627-80-7
|
Eptifibatide
|
Innovators:
Millennium Pharma
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMF
|
|
|
|
129-51-1
|
Ergometrine (ergonovine) maleate
|
Innovators:
Novartis
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCanada DMFCEPOther
|
|
|
|
379-79-3
|
Ergotamine tartrate
|
Innovators:
Novartis
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCEPOther
|
|
|
|
183319-69-9
|
Erlotinib hcl
|
Innovators:
Roche
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMF
|
|
|
|
138729-47-2
|
Eszopiclone
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCanada DMFJapan DMF
|
|
|
|
41340-25-4
|
Etodolac
|
Innovators:
Pfizer
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
CEPJapan DMFUS DMFEU DMFOther
|
|
|
|
33419-42-0
|
Etoposide
|
Innovators:
Bristol-Myers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCEPOther
|
|
|
|
141732-74-9
|
Exenatide
|
Innovators:
Amylin Pharma
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFEU DMFKorea DMFOther
|
|
|
|
163222-33-1
|
Ezetimibe
|
Innovators:
Merck & Co.
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMFUS DMFCanada DMFBrazil DMFOther
|
|
|
| | |
104227-87-4
|
Famciclovir
|
Innovators:
Novartis
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Canada DMFEU DMFUS DMFKorea DMF
|
|
|
|
144060-53-7
|
Febuxostat
|
Innovators:
Teijin Pharma
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Canada DMFUS DMFEU DMFOther
|
|
|
|
162359-55-9
|
Fingolimod
|
Innovators:
Mitsubishi Tanabe Pharma
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY US
|
Available dmf:
DMFCanada DMFOther
|
|
|
|
75607-67-9
|
Fludarabine phosphate
|
Innovators:
Southern Research Institute
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
514-36-3
|
Fludrocortisone acetate
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMF
|
|
|
|
3385-03-3
|
Flunisolide
|
Innovators:
Hoffmann-La Roche
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
Q - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
Canada DMFEU DMFUS DMFOther
|
|
|
|
67-73-2
|
Fluocinolone acetonide
|
Innovators:
Valeant
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)N - OPHTHALMICP - OTICT - VAGINAL/INTRA-UTERINE (Women Health)
|
Available dmf:
US DMFJapan DMFEU DMFOther
|
|
|
|
356-12-7
|
Fluocinonide
|
Innovators:
Medicis Pharma
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMFOther
|
|
|
|
3801-06-7
|
Fluorometholone acetate
|
Innovators:
Alcon
|
Therapeutic category:
S-SENSORY
|
Formulation:
ORGANS N - OPHTHALMIC
|
Available dmf:
US DMFCanada DMFEU DMFOther
|
|
|
|
426-13-1
|
Fluorometholone base
|
Innovators:
Novartis
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
Japan DMFEU DMFOther
|
|
|
|
51-21-8
|
Fluorouracil
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFJapan DMFCEPOther
|
|
|
|
56296-78-7
|
Fluoxetine hcl
|
Innovators:
Eli Lilly
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFCEPKorea DMFEU DMF
|
|
|
|
397864-44-7
|
Fluticasone furoate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
Q - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
-
|
|
|
|
80474-14-2
|
Fluticasone propionate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)Q - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFJapan DMFCEPEU DMF
|
|
|
|
93957-55-2
|
Fluvastatin sodium
|
Innovators:
Novartis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCanada DMFCEPOther
|
|
|
|
61717-82-9
|
Fluvoxamine maleate
|
Innovators:
Solvay
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFJapan DMF
|
|
|
|
183814-30-4
|
Formoterol fumarate
|
Innovators:
Novartis
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFCEPCanada DMFJapan DMFKorea DMFOther
|
|
|
|
129453-61-8
|
FulvestrantAstra
|
Innovators:
Zeneca
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
54-31-9
|
Furosemide
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCanada DMFCEP
|
|
|
| | |
1953-04-4
|
Galantamine hbr
|
Innovators:
Sanochemia Pharmazeutika
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFCEPKorea DMFOther
|
|
|
|
122111-03-9
|
Gemcitabine hcl
|
Innovators:
Eli Lilly
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFUS DMFJapan DMFCEPKorea DMFCanada DMFOther
|
|
|
| |
52-86-8
|
Haloperidol
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFUS DMFCanada DMFJapan DMFOther
|
|
|
|
74050-97-8
|
Haloperidol decanoate
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
58-93-5
|
Hydrochlorothiazide
|
Innovators:
Novartis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFCanada DMFCEPKorea DMFJapan DMFOther
|
|
|
|
936563-96-1
|
Ibrutinib
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
138614-30-9
|
Icatibant
|
Innovators:
Shire
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMF
|
|
|
|
57852-57-0
|
Idarubicin hcl
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFUS DMFCanada DMFOther
|
|
|
|
220127-57-1
|
Imatinib mesylate
|
Innovators:
Novartis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCanada DMFJapan DMFEU DMFKorea DMFOther
|
|
|
|
113-52-0
|
Imipramine hcl
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY US DMFCEP
|
Available dmf:
US DMFCEP
|
|
|
|
99011-02-60
|
Imiquimod
|
Innovators:
3M
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFCanada DMFEU DMF
|
|
|
|
138402-11-6
|
Irbesartan
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Canada DMFCEPEU DMFUS DMFOther
|
|
|
|
1201902-80-8
|
Ixazomib
|
Innovators:
CitrateTakeda
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
| |
32780-64-6
|
Labetalol hcl
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
CEPUS DMFJapan DMF
|
|
|
|
84057-84-1
|
Lamotrigine
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMF
|
|
|
|
127984-74-1
|
Lanreotide acetate
|
Innovators:
Ipsen Group
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
-
|
|
|
|
103577-45-3
|
Lansoprazole
|
Innovators:
Takeda
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCEPEU DMFOther
|
|
|
|
130209-82-4
|
Latanoprost
|
Innovators:
Pfizer
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
US DMFEU DMFCanada DMF
|
|
|
|
860005-21-6
|
Latanoprostene bunod
|
Innovators:
Valeant
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
-
|
|
|
|
1256388-51-8
|
Ledipasvir
|
Innovators:
Gilead Sciences
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
112809-51-5
|
Letrozole
|
Innovators:
Novartis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
59-92-7
|
Levodopa
|
Innovators:
Roche
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING CEP
|
Available dmf:
Canada DMFUS DMFBrazil DMFOther
|
|
|
|
100986-85-4
|
Levofloxacin
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)N - OPHTHALMIC
|
Available dmf:
US DMFJapan DMFCanada DMFEU DMFOther
|
|
|
|
50293-90-8
|
Levosalbutamol hcl (levalbuterol)
|
Innovators:
Sunovion Pharma
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMF
|
|
|
|
851199-60-5
|
Linaclotide
|
Innovators:
Forest Labs
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
668270-12-0
|
Linagliptin
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFKorea DMF
|
|
|
|
165800-03-3
|
Linezolid
|
Innovators:
Pfizer
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
-
|
|
|
|
34552-83-5
|
Loperamide hcl
|
Innovators:
McNeil
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
124750-99-8
|
Losartan potassium
|
Innovators:
Merck & Co.
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Japan DMFEU DMFCEPCanada DMFUS DMFKorea DMFOther
|
|
|
|
75330-75-5
|
Lovastatin
|
Innovators:
Merck & Co.
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCEPOther
|
|
|
|
367514-88-3
|
Lurasidone
|
Innovators:
Sumitomo Dainippon Pharma
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
61337-67-5
|
Mirtazapine
|
Innovators:
Schering-Plough
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCEPEU DMFOther
|
|
|
|
50-07-7
|
Mitomycin
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPCanada DMF
|
|
|
|
102113?40?6
|
Mometasone furoate
|
Innovators:
Schering-Plough
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)Q - NASAL TOPICALR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFCEPEU DMFJapan DMF
|
|
|
|
151567-02-1
|
Montelukast sodium
|
Innovators:
Merck & Co.
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFCEPEU DMFKorea DMFJapan DMFOther
|
|
|
|
12650-69-0
|
Mupirocin
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
CEPEU DMFUS DMFBrazil DMFOther
|
|
|
|
115074-43-6
|
Mupirocin calcium
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)Q - NASAL TOPICAL
|
Available dmf:
US DMFCEPEU DMFCanada DMFOther
|
|
|
|
115007-34-6
|
Mycophenolate mofetil
|
Innovators:
Roche
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFJapan DMFCanada DMFCEPOther
|
|
|
|
24280-93-1
|
Mycophenolate sodium
|
Innovators:
Novartis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFOther
|
|
|
|
441798-33-0
|
Macitentan
|
Innovators:
Actelion Pharma
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
71-58-9
|
Medroxyprogesterone acetate
|
Innovators:
Pfizer
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARYG - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFCEPEU DMF
|
|
|
|
595-33-5
|
Megestrol acetate
|
Innovators:
Par Pharma
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFCEPEU DMF
|
|
|
|
41100-52-1
|
Memantine hcl
|
Innovators:
Merz Pharma
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
EU DMFUS DMFCanada DMFOtherx
|
|
|
|
41372-08-1
|
Methyldopax
|
Innovators:
C-CARDIOVASCULAR SYSTEM
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY CEPUS
|
Available dmf:
DMFJapan DMFOther
|
|
|
|
57432-61-8
|
Methylergonovine maleate
|
Innovators:
Novartis
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCEPOther
|
|
|
|
2921-57-5
|
Methylprednisolone hemisuccinate
|
Innovators:
Pfizer
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMF
|
|
|
|
2375-03-3
|
Methylprednisolone sodium
|
Innovators:
succinatePfizer
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
EU DMFJapan DMFOther
|
|
|
|
98418-47-4
|
Metoprolol succinate
|
Innovators:
Astra Zeneca
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING US DMFCEPEU DMFOther
|
Available dmf:
US DMFCEPEU DMFOther
|
|
|
|
56392-17-7
|
Metoprolol tartrate
|
Innovators:
Novartis
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
CEPUS DMFCanada DMFOther
|
|
|
|
208538-73-2
|
Micafungin sodium
|
Innovators:
Astellas
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
-
|
|
|
| | |
22204-53-1
|
Naproxen
|
Innovators:
Hoffmann-La Roche
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGM - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
26159-34-2
|
Naproxen sodium
|
Innovators:
Hoffmann-La Roche
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFCEPCanada DMF
|
|
|
|
105816-04-4
|
Nateglinide
|
Innovators:
Ajinomoto
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFKorea DMF
|
|
|
|
82752-99-6
|
Nefazodone hcl
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCanada DMF
|
|
|
|
27848-84-6
|
Nicergoline
|
Innovators:
Pfizer
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPJapan DMFOther
|
|
|
|
21829-25-4
|
Nifedipine
|
Innovators:
Bayer
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFCEPCanada DMFJapan DMF
|
|
|
|
923288-95-3
|
Nilotinib hcl
|
Innovators:
Novartis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
656247-17-5
|
Nintedanib
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
35189-28-7
|
Norgestimate
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFCanada DMF
|
|
|
|
79517-01-4
|
Octreotide acetate
|
Innovators:
Novartis
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
132539-06-1
|
Olanzapine
|
Innovators:
Eli Lilly
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
CEPUS DMFEU DMFCanada DMFKorea DMFOther
|
|
|
|
144689-63-4
|
Olmesartan medoxomil
|
Innovators:
Daiichi
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFBrazil DMFKorea DMFOther
|
|
|
|
869477-96-3
|
Olodaterol
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
-
|
|
|
|
73590-58-6
|
Omeprazole
|
Innovators:
Astra Zeneca
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPJapan DMF
|
|
|
|
99614-02-5
|
Ondansetron base
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMF
|
|
|
|
103639-04-9
|
Ondansetron hcl
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCEPKorea DMFEU DMFOther
|
|
|
|
61825-94-3
|
Oxaliplatin
|
Innovators:
Sanofi Aventis
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPEU DMFJapan DMF
|
|
|
| |
33069-62-4
|
Paclitaxel
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFCEPCanada DMFKorea DMFOther
|
|
|
|
571190-30-2
|
Palbociclib
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
144598-75-4
|
Paliperidone
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
B - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMF
|
|
|
|
199739-10-1
|
Paliperidone palmitate
|
Innovators:
Johnson & Johnson
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
-
|
|
|
|
135729-62-3
|
Palonosetron hcl
|
Innovators:
Roche
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFKorea DMFEU DMFOther
|
|
|
|
40391-99-9
|
Pamidronic acid
|
Innovators:
Gador
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFKorea DMFOther
|
|
|
|
15500-66-0
|
Pancuronium bromide
|
Innovators:
3M
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFCEPCanada DMFOther
|
|
|
|
199387-73-0
|
Pantoprazole magnesium
|
Innovators:
Takeda
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
138786-67-1
|
Pantoprazole sodium
|
Innovators:
Pfizer
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCEPOther
|
|
|
|
131918-61-1
|
Paricalcitol
|
Innovators:
Abbvie
|
Therapeutic category:
H-SYSTEMIC HORMONAL PREPAR
|
Formulation:
A - ORAL SOLID ORDINARYF - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMF
|
|
|
|
78246-49-9
|
Paroxetine hcl
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTINGD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
US DMFJapan DMFEU DMFOther
|
|
|
|
357166-30-4
|
Pemetrexed disodium
|
Innovators:
Eli Lilly
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFEU DMFOther
|
|
|
|
942063-28-7
|
Perampanel
|
Innovators:
Eisai
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMF
|
|
|
|
66104-23-2
|
Pergolide mesylate
|
Innovators:
Eli Lilly
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCanada DMFCEP
|
|
|
|
112529-15-4
|
Pioglitazone HCl
|
Innovators:
Takeda
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFJapan DMFCanada DMFEU DMFOther
|
|
|
|
146464-95-1
|
Pralatrexate
|
Innovators:
Allos
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMF
|
|
|
|
150322-43-3
|
Prasugrel base
|
Innovators:
Daiichi
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
1060616-79-6
|
Prasugrel HBr
|
Innovators:
Daiichi
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMFUS DMF
|
|
|
|
389574-19-0
|
Prasugrel HCl
|
Innovators:
Daiichi
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
EU DMFUS DMF
|
Available dmf:
EU DMFUS DMF
|
|
|
|
81131-70-6
|
Pravastatin sodium
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFJapan DMFCEPKorea DMFEU DMFOther
|
|
|
|
2920-86-7
|
Prednisolone hemisuccinate
|
Innovators:
H-SYSTEMIC HORMONAL PREPAR
|
Therapeutic category:
F - PARENTERAL ORDINARY (Injectables)T - VAGINAL/INTRA-UTERINE (Women Health)
|
Formulation:
Other
|
Available dmf:
-
|
|
|
|
148553-50-8
|
Pregabalin
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMFOther
|
|
|
|
57-66-9
|
Probenecid
|
Innovators:
Merck & Co.
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFCEP
|
|
|
|
99300-78-4
|
Venlafaxine hcl
|
Innovators:
Pfizer
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFCEPEU DMFOther
|
|
|
|
165800-06-6
|
Zoledronic acid
|
Innovators:
Novartis
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFJapan DMFEU DMFCanada DMFOther
|
|
|
| | |
111974-72-2
|
Quetiapine fumarate
|
Innovators:
Astra Zeneca
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMFOther
|
|
|
| | |
128517-07-7
|
Romidepsin
|
Innovators:
Astellas
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMF
|
|
|
|
147098-20-2
|
Rosuvastatin calcium
|
Innovators:
Astra Zeneca
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
CEPUS DMFJapan DMFEU DMFOther
|
|
|
|
99755-59-6
|
Rotigotine
|
Innovators:
UCB Pharma
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
J - OTHER SYSTEMIC
|
Available dmf:
-
|
|
|
|
115436-72-1
|
Risedronate sodium
|
Innovators:
Procter & Gamble
|
Therapeutic category:
M-MUSCULO-SKELETAL SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
EU DMFCanada DMFUS DMFKorea DMF
|
|
|
|
106266-06-2
|
Risperidone
|
Innovators:
Cilag
|
Therapeutic category:
N-CENTRAL NERVOUS SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)G - PARENTERAL LONG-ACTING (Injectables)
|
Available dmf:
US DMFJapan DMFCEPKorea DMFEU DMFOther
|
|
|
|
366789-02-8
|
Rivaroxaban
|
Innovators:
Bayer
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
Korea DMF
|
|
|
|
18559-94-9
|
Salbutamol (albuterol)
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
Canada DMFOther
|
|
|
|
51022-70-9
|
Salbutamol (albuterol) sulfate
|
Innovators:
GlaxoSmithKline
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
EU DMFUS DMFCanada DMFJapan DMFOther
|
|
|
|
361442-04-8
|
Saxagliptin
|
Innovators:
Bristol Meyers Squibb
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
Korea DMF
|
|
|
|
475086-01-2
|
Selexipag
|
Innovators:
Actelion Pharmaceuticals
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
171599-83-0
|
Sildenafil citrate
|
Innovators:
Pfizer
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)
|
Available dmf:
CEPUS DMFEU DMFCanada DMFOther
|
|
|
|
22199-08-2
|
Silver sulfadiazine
|
Innovators:
King Pharma
|
Therapeutic category:
D-DERMATOLOGICALS
|
Formulation:
D - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
US DMFEU DMFOther
|
|
|
|
65666-07-1
|
Silymarin
|
Innovators:
Madaus
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYD - ORAL LIQUID ORDINARY (Drops/ Syrups/ Solubles…)F - PARENTERAL ORDINARY (Injectables)M - TOPICAL/ DERMATOLOGICAL (Ointements/ Creams/ Lotions/ Gels…)
|
Available dmf:
CEPEU DMFKorea DMFOther
|
|
|
|
79902-63-9
|
Simvastatin
|
Innovators:
Merck & Co.
|
Therapeutic category:
C-CARDIOVASCULAR SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
CEPJapan DMFUS DMFKorea DMFEU DMF
|
|
|
|
1240039-02-4
|
Sitagliptin malate
|
Innovators:
Merck & Co.
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
EU DMF
|
|
|
|
654671-77-9
|
Sitagliptin phosphate
|
Innovators:
Merck & Co.
|
Therapeutic category:
A-ALIMENTARY TRACT & METABOL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMF
|
|
|
|
1190307-88-0
|
Sofosbuvir
|
Innovators:
Gilead Sciences
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
-
|
|
|
|
242478-38-2
|
Solifenacin succinate
|
Innovators:
Astellas
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARYB - ORAL SOLID LONG-ACTING
|
Available dmf:
US DMFEU DMFCanada DMFKorea DMF
|
|
|
|
475207-59-1
|
Sorafenib tosylate
|
Innovators:
Bayer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMF
|
|
|
|
557795-19-4
|
Sunitinib base
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMF
|
|
|
|
341031-54-7
|
Sunitinib malate
|
Innovators:
Pfizer
|
Therapeutic category:
L-ANTINEOPLASTIC & IMMUNOMODUL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
EU DMFUS DMF
|
|
|
|
37686-85-4
|
Terguride
|
Innovators:
Spofa United Pharmaceutical Works
|
Therapeutic category:
G-GENITO-URINARY SYSTEM & SEX HORMONAL
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFEU DMFJapan DMF
|
|
|
|
274693-27-5
|
Ticagrelor
|
Innovators:
Astra Zeneca
|
Therapeutic category:
B-BLOOD AND BLOOD FORMING ORGANS
|
Formulation:
A - ORAL SOLID ORDINARY
|
Available dmf:
US DMFKorea DMF
|
|
|
|
220620-09-7
|
Tigecycline
|
Innovators:
Pfizer
|
Therapeutic category:
J-GENERAL ANTI-INFECTIVES SYSTEM
|
Formulation:
F - PARENTERAL ORDINARY (Injectables)
|
Available dmf:
US DMFEU DMFCanada DMFOther
|
|
|
|
26921-17-5
|
Timolol maleate
|
Innovators:
Merck & Co.
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMIC
|
Available dmf:
CEPUS DMFCanada DMFJapan DMFKorea DMF
|
|
|
|
136310-93-5
|
Tiotropium bromide
|
Innovators:
Boehringer Ingelheim
|
Therapeutic category:
R-RESPIRATORY SYSTEM
|
Formulation:
R - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFEU DMF
|
|
|
|
32986-56-4
|
Tobramycin
|
Innovators:
Akorn
|
Therapeutic category:
S-SENSORY ORGANS
|
Formulation:
N - OPHTHALMICR - LUNG ADMINISTRATION (Inhalation)
|
Available dmf:
US DMFJapan DMFCEPKorea DMFEU DMF
|
|
|
|
124937-52-6
|
Tolterodine tartrate
| | |